Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data ...
All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.
Mounjaro surpassed Keytruda as the world’s top-selling medicine, driven by soaring global demand for obesity and diabetes treatments.
Merck (NYSE:MRK) plans to present more than 100 oncology abstracts at the 2026 ASCO Annual Meeting. The company will share ...
BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
The gap between US drug prices and those abroad is not a market outcome — it is the result of deliberate political and ...
Shirley Xerxes was one of the first in the UK to receive the injectable form of Keytruda on the NHS A new injectable form of a key cancer drug could see thousands of NHS patients across the UK ...
12d
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients
Dr. Kirk Shepard (Chief Medical Officer) detailed a pivotal change to the Phase III VERSATILE-003 study design: “we adopted an amendment to our VERSATILE-003 trial, revising the design to incorporate ...
The United States Patent Trial and Appeal Board (PTAB) has issued its first invalidation ruling on the core 'MDASE' patent ...
RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP ...
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results